Canada's standard PCT national-phase deadline is 30 months from the earliest priority date. CIPO also provides a specific late-entry reinstatement mechanism within 12 months after that deadline when statutory conditions are met.
| Patent office | Canadian Intellectual Property Office (CIPO) |
|---|---|
| Entry deadline | 30 months from the earliest priority date; CIPO describes a potential reinstatement route within 12 months after that deadline if statutory requirements are met. |
| Language / translation | English or French; translation is required where the international application is not in one of those languages. |
| Representation | CIPO states that all applicants may use a patent agent and that an applicant who is not the inventor must appoint a patent agent. |
| Portfolio question | Canada can be strategically important for North American market coverage, technology companies, life sciences, energy, natural resources, AI and cross-border commercialization. |
This page separates current national-phase procedure from strategic filing considerations. Deadlines, fees and office rules can change, so consequential filing decisions should be verified against the official sources listed below.
CIPO states that the time limit for national-phase entry is 30 months from the earliest priority date, or from the international filing date where no priority claim was made. Applicants should still set an earlier internal deadline for translation, agent instructions, maintenance fees and applicant information.
CIPO states that an applicant may be able to enter the national phase within 12 months after the 30-month deadline by requesting reinstatement, stating that the failure was unintentional and paying the prescribed reinstatement and other required fees. This is an important country-specific feature, but it should not be used as the planned filing timetable.
If the international application is not in English or French, CIPO requires a translation into one of those languages for national entry. This can reduce translation burden for applicants whose PCT application is already in English or French and is one reason Canada may be operationally simpler than jurisdictions requiring a new language translation.
CIPO identifies the basic national fee as a core entry requirement and notes that maintenance fees can also be due depending on the application timeline. Applicants should verify the current fee schedule before filing because official charges can change.
CIPO states that all applicants can use a patent agent and that an applicant who is not the inventor must appoint a patent agent. This requirement should be checked early where the applicant is a company or other assignee rather than the individual inventor.
After entry, CIPO examines the application under the Patent Act and Patent Rules. Prior-art and patentability issues are considered under Canadian law. International search results can be useful but do not replace Canadian examination.
Canada is often evaluated together with the United States, but the filing decision should remain independent. Canadian market size, competitor activity, manufacturing, licensing, technology clusters and enforcement value should be compared with the cost of prosecution and maintenance.
Canada may be important for AI, software, telecom, energy, clean technology, mining, life sciences and other sectors with significant Canadian research or market activity. The value of a Canadian patent depends on where commercial activity actually occurs.
Retain Canada where North American market coverage, Canadian customers, competitors, R&D, licensing or enforcement justify the cost. The lack of translation cost for English/French PCT applications can improve the economics, but it should not replace substantive commercial analysis.
Before entering the national phase in Canada, re-check the controlling deadline, translation requirements, required application documents, representation rules, official fees and any available restoration or extension mechanism against the current patent-office or WIPO materials linked on this page. A national-phase decision should also confirm that the application being entered is the correct international application and that the claims, description and drawings support the commercial product. Procedural accuracy and portfolio value are separate questions, so both should be reviewed before fees are committed.
Entry into Canada should be tied to a commercial reason. Relevant evidence can include expected revenue, manufacturing, technically significant infrastructure, competitors, licensees, investors, regulated-market access and the location of acts that could support infringement evidence. A large market is not automatically a high-value patent market for every invention. The strongest decision record states what commercial leverage the right is expected to create and what portfolio cost will be required through prosecution and maintenance.
The PCT application may contain broad claims, but the commercially useful position in Canada can depend on who performs the claimed steps and how the product is deployed. Server-side, device, system, composition, method or manufacturing claims can create different enforcement positions depending on the technology. Before examination begins, identify the product features that matter, the likely competitor implementation and the evidence that could later show use of the claimed invention.
The national-phase deadline is not only a procedural event. It is a natural point to review product-market fit, licensing discussions, competitor activity, financing, technical changes and prior-art developments. If the invention has changed materially since the priority filing, prosecution strategy should be adjusted within the support available in the original disclosure. Jurisdictions that no longer support a clear business objective can be removed, allowing budget to move toward stronger markets or newer inventions.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Before acting on this page, identify the exact decision it is meant to support, the official source that controls any procedural requirement, the technical or commercial evidence that justifies the chosen jurisdiction, and the next deadline or document required. A clear decision record should also state what would cause the strategy to change. This makes the research usable during later prosecution, national-phase selection, budgeting and portfolio review rather than leaving it as a static summary.
Use official filing rules together with market, manufacturing, competitor, licensing, enforcement and technology considerations before committing to long-term prosecution cost.
rd (at) patentbusinesslawyer (dot) com
